India’s biotech sector is moving into a phase where execution matters more than ambition. In 2026, the leaders to watch are those managing scale, pressure, and responsibility. This list highlights ten innovators shaping how science, medicine...
Eli Lilly has entered into a huge collaboration with Nimbus Therapeutics to develop a new obesity pill. This action assists Lilly in its quest to get out of injectable weight-loss drugs. The transaction, which was announced today, is aimed at...
Wegovy pill is now available in the U.S., bringing proven GLP 1 weight loss science into a simple once daily tablet. Approved on December 22, 2025, this new option expands treatment choices for more than 100 million Americans living with obesity...
Intelligent Bio Solutions has entered a major global manufacturing partnership with Syrma Johari MedTech Ltd, a move set to sharply reduce costs, improve margins, and speed up its planned US market entry. Announced today, the agreement...
The Union Health Ministry is in discussions with state governments on the possibility of granting additional time to certain pharmaceutical manufacturers to comply with revised Good Manufacturing Practices (GMP) norms under Schedule M of the Drug...
Dr. Reddy’s Labs receives a USFDA CRL for AVT03 denosumab biosimilar, citing manufacturing inspection issues, delaying approval in the key US biologics market.
Cupid has received in-principle approval from its Board of Directors to establish a new FMCG manufacturing facility in the Kingdom of Saudi Arabia (KSA), marking the company’s first manufacturing venture outside India.
Amneal Pharmaceuticals Inc. got an approval from the FDA for two denosumab biosimilars, growing their biosimilar offerings in the US.
Ajanta Pharma partners with Biocon to launch Semaglutide in emerging markets, boosting GLP-1 therapy access, therapeutic leadership, and commercial growth in diabetes care.
In 2025, India’s pharmaceutical sector is demonstrating remarkable dynamism, driven by a blend of global collaborations and homegrown innovation.